# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Beyfortus is anticipated to be available during the upcoming 2024-2025 RSV season.
The trial included patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) epidermal growth factor receptor-m...
The trial included patients with previously untreated advanced or metastatic non-small cell lung cancer (NSCLC) without actiona...
The CRL did not request additional analysis or reanalysis of the Phase 3 CHAMPION-NMOSD trial data and did not raise concerns...
Earlier today, AstraZeneca plc (NASDAQ: AZN)
AstraZeneca Plc's (NASDAQ: AZN) unit Alexion has
Ionis and AstraZeneca will continue to jointly develop and commercialize eplontersen in the U.S. The companies are successfully...
https://www.astrazeneca.com/media-centre/press-releases/2023/alexion-enters-gene-therapy-agreement-with-pfizer.html